2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual

Partnering Events:

TechConnect Summit
Clean Technology 2008

Composite Nanodevices in Imaging and Treatment of Cancer

L.P. Balogh, W. Lesniak, M.T. Ould Ely, M. O’Donnell, C. Tse, M. Zohdy, J.Y. Ye, M.T. Kariapper, M.K. Khan
Roswell Park Cancer Institute, US

dendrimer, composite, nanodevice, targeted delivery, nanobrachytherapy, photomechanical therapy

Abstract: In this talk, the fabrication, characterization, utility, properties, biodistribution and in vivo testing of some of the composite nanodevices that are being developed at the Roswell Park Cancer Institute will be presented. As nanotechnology permits the creation of “smart” materials and multifunctional devices, nanoscience has an enormous scientific and practical future in medicine, especially in biomedical imaging, targeted drug delivery, novel treatments, device compatibility, sensors, and tissue engineering. In this talk, the concept of targeted delivery of multifunctional composite nanodevices (CND) will be discussed using examples of anticancer nanodevices that can carry labels, imaging and/or therapeutic agents to cancer cells. Dendrimer nanocomposite materials are nanosized organic-inorganic hybrids that combine chemical and physical properties of the guest molecules or atoms and their host template in a synergistic way. Physical interactions of the nanoparticle with the environment (solubility, biodistribution) are dominated by the contact surface of the template dendrimer molecules. As a consequence, encapsulated inorganic nanoparticles can be manipulated as if they were organic ones, and composite nanoparticles with either cationic, anionic, neutral, lipophilic, lipophobic or mixed surfaces can be synthesized. It is a unique advantage in the optimization of these nanodevices that components can be separately optimized than combined. Our anticancer nanodevices are made of dendrimer nanocomposites of defined size and net surface charge and biologically active molecules, such as multiple small peptides. CNDs carry targeting moieties (e.g., small peptides) and may carry biologic labels (e.g., biotin), to predetermined targets. To effectively target these anticancer CNDs one must reproducibly control the composition, size, surface (net charge and substitution), and architecture of the composite nanoparticles. To achieve the desirable biodistribution, narrow distribution of the above properties is also a must. A key issue is the characterization of nanodevices using multiple techniques relevant for the required biologic information. Examples will include novel treatment mechanisms as nanobrachytherapy (NBT) and photomechanical therapy (PMT).

Nanotech 2008 Conference Program Abstract